β-Caryophyllene, a phytocannabinoid attenuates oxidative stress, neuroinflammation, glial activation, and salvages dopaminergic neurons in a rat model of Parkinson disease.
Parkinson disease (PD) is a neurodegenerative disease characterized by progressive dopaminergic neurodegeneration in the substantia nigra pars compacta (SNc) area. The present study was undertaken to evaluate the neuroprotective effect of β-caryophyllene (BCP) against rotenone-induced oxidative stress and neuroinflammation in a rat model of PD. In the present study, BCP was administered once daily for 4 weeks at a dose of 50 mg/kg body weight prior to a rotenone (2.5 mg/kg body weight) challenge to mimic the progressive neurodegenerative nature of PD. Rotenone administration results in oxidative stress as evidenced by decreased activities of superoxide dismutase, catalase, and depletion of glutathione with a concomitant rise in lipid peroxidation product, malondialdehyde. Rotenone also significantly increased pro-inflammatory cytokines in the midbrain region and elevated the inflammatory mediators such as cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) in the striatum. Further, immunohistochemical analysis revealed loss of dopaminergic neurons in the SNc area and enhanced expression of ionized calcium-binding adaptor molecule-1 (Iba-1) and glial fibrillary acidic protein (GFAP), indicators of microglia activation, and astrocyte hypertrophy, respectively, as an index of inflammation. However, treatment with BCP rescued dopaminergic neurons and decreased microglia and astrocyte activation evidenced by reduced Iba-1 and GFAP expression. BCP in addition to attenuation of pro-inflammatory cytokines and inflammatory mediators such as COX-2 and iNOS, also restored antioxidant enzymes and inhibited lipid peroxidation as well as glutathione depletion. The findings demonstrate that BCP provides neuroprotection against rotenone-induced PD and the neuroprotective effects can be ascribed to its potent antioxidant and anti-inflammatory activities.
Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, PO Box: 17666, Al Ain, UAE.
Shreesh
S
Ojha
Department of Biochemistry, College of Medicine and Health Sciences, United Arab Emirates University, PO Box: 17666, Al Ain, UAE.
Hayate
H
Javed
Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, PO Box: 17666, Al Ain, UAE.
Sheikh
S
Azimullah
Department of Biochemistry, College of Medicine and Health Sciences, United Arab Emirates University, PO Box: 17666, Al Ain, UAE. ehaque@uaeu.ac.ae.
M Emdadul
ME
Haque
D000818:Animals; D002186:Cannabinoids / Q000494:pharmacology*; D059290:Dopaminergic Neurons / Q000378:metabolism* / Q000473:pathology; D008297:Male; D009457:Neuroglia / Q000378:metabolism* / Q000473:pathology; D018384:Oxidative Stress / Q000187:drug effects*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D000081223:Polycyclic Sesquiterpenes; D051381:Rats; D012402:Rotenone / Q000009:adverse effects / Q000494:pharmacology; D012717:Sesquiterpenes / Q000494:pharmacology*
D002186:Cannabinoids; D000081223:Polycyclic Sesquiterpenes; D012717:Sesquiterpenes; D012402:Rotenone; C024714:caryophyllene
Neurodegeneration; Neurotoxicity; Parkinson disease; Rotenone; β-Caryophyllene